FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study
Hepatobiliary & Pancreatic Diseases International
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Гастроэнтерология»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study. // Hepatobiliary & Pancreatic Diseases International. – URL: https://www.sciencedirect.com/science/article/pii/S1499387226001244?dgcid=rss_sd_all
FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study. Hepatobiliary & Pancreatic Diseases International. https://www.sciencedirect.com/science/article/pii/S1499387226001244?dgcid=rss_sd_all
“FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study.” Hepatobiliary & Pancreatic Diseases International.
@article{article48274,
title = {FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study},
journal = {Hepatobiliary \& Pancreatic Diseases International},
url = {https://www.sciencedirect.com/science/article/pii/S1499387226001244?dgcid=rss_sd_all}
}